Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 540 Avis Dr a, Ann Arbor, MI 48108, USA
- Website
- tsr-labs.com
- Founded
- 1986
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Definitive Contract MD170199503DDAMD1795C5060 | Department of the Army | $70,000 |
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Tsrl, Inc., doing business as Therapeutic Systems Research Laboratories, is a woman-owned small business based in Ann Arbor, Michigan, that develops novel pharmaceutical delivery systems and therapeutic compounds for federal health research as a prime grant recipient with the National Institutes of Health and the Centers for Disease Control and Prevention. The company operates exclusively in the federal grant space (100% prime recipient awards) with no federal contract presence.
Tsrl specializes in transdermal and microneedle drug delivery platforms, with a portfolio anchored in infectious disease and chronic-disease therapeutics. Recent representative work includes a $299,608 Phase 1 project grant from the CDC (CFDA 93.318, Protecting and Improving Health Globally) awarded September 30, 2026, to develop an optimized zanamivir microarray patch formulation for single-application influenza treatment, running through September 2028. Tsrl holds concurrent cooperative agreement funding from the National Institute of Allergy and Infectious Diseases (NIAID) for a Phase 1 clinical trial assessing pharmacokinetics, safety, and tolerance of a zanamivir transdermal system in healthy subjects, awarded July 10, 2024, with ultimate completion August 31, 2028. The company also completed a NIAID project grant (awarded August 1, 2023, completed January 31, 2027) developing a novel self-applied zanamivir microarray patch for flu treatment. Prior work spans microneedle delivery of trospium chloride for overactive bladder disease (dual awards from the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Child Health and Human Development, both September 2022), novel heparin-reversal therapeutics using proprietary polyanion modulating dendrimer (POMOD) chemistry (National Heart Lung and Blood Institute, September 2022), and synthetic high-density lipoprotein development for sepsis treatment (National Institute of General Medical Sciences, February 2022).
Customer concentration is extreme: 85% of awards flow from two funding paths within the Department of Health and Human Services — the National Institutes of Health broadly and NIAID specifically. The vendor has worked with nine distinct federal agencies, but NIH and NIAID dominate both volume and funding. Four awards reach ultimate completion within the next twenty-four months and face recompete exposure. All work is performed in Ann Arbor. Tsrl has no presence on federal contract vehicles, IDIQs, GWACs, or schedules; revenue flows entirely through competitive federal research grants in biomedical research and development.
Quick answers
Is Tsrl, Inc. registered in SAM.gov?
Yes. Tsrl, Inc.'s SAM.gov registration is active through October 5, 2027.
What is Tsrl, Inc.'s CAGE code?
Tsrl, Inc.'s CAGE code is 02NM7, and its Unique Entity ID (UEI) is TP74UMNGJDJ1.
What is Tsrl, Inc.'s most recent federal award?
Tsrl, Inc.'s most recent federal grant award is Optimized zanamivir microarray patch (map) formulation for single application treatment of the flu (R43IP001280), from Office of Financial Resources (CDC), on September 30, 2026.
On GovTribe
See Tsrl, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors